Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ASCELIA PHARMA AB
No Price
Closing Price XSTO 30.04.2026:
3,00 SEK
30.04.2026 10:59
Current Prices from ASCELIA PHARMA AB
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ STOCKHOLM AB
ACE.ST
SEK
30.04.2026 10:59
3,00 SEK
-
Share Float & Liquidity
Free Float92,26 %
Shares Float117,05 M
Shares Outstanding126,87 M
Company Profile for ASCELIA PHARMA AB Share
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
